$2.1 Billion by 2035 — How Next-Generation Sequencing and Liquid Biopsy Are Transforming Precision Medicine

$2.1 B * * ∣ * * 12.5$ 0.65B
Market Value by 2035 | CAGR (2026-2035) | Market Value in 2025

MiRNA Sequencing Assay Market

Key Takeaways

MiRNA Sequencing Assay Market is projected to reach USD 2.1 billion by 2035 at a 12.5% CAGR .
Next-generation sequencing (NGS) dominates the technology segment; real-time PCR (qPCR) is the fastest-growing .
Oncology and cancer research applications lead market demand; cardiovascular and neurological diseases are rapidly growing .
Illumina, Thermo Fisher Scientific, Qiagen, Agilent Technologies, and Bio-Rad lead the competitive landscape .
North America holds the largest market share; Asia-Pacific is the fastest-growing region .

The MiRNA Sequencing Assay Market is projected to grow from USD 0.65 billion in 2025 to USD 2.1 billion by 2035 at a 12.5% CAGR , driven by increasing prevalence of cancer and chronic diseases, growing demand for liquid biopsy-based diagnostics, and the adoption of MiRNA Sequencing and Liquid Biopsy technologies that enable non-invasive disease detection, early diagnosis, and personalized treatment monitoring across oncology, cardiovascular, and neurological applications worldwide .

Market Size and Forecast (2025-2035)

*Source: Market Research Future *

Segment & Technology Breakdown

*Source: Market Research Future *

What Is Driving the MiRNA Sequencing Assay Market Demand?

Increasing Cancer Prevalence: The global cancer burden continues to rise, with approximately 19.3 million new cases and 10 million cancer deaths reported in 2020. MiRNA sequencing offers non-invasive liquid biopsy alternatives to traditional tissue biopsies, driving demand for early detection and monitoring tools .

Advancements in Next-Generation Sequencing (NGS): NGS technologies have dramatically reduced sequencing costs from $100 mi ll i o n p er g e n o m e in 2001 t o u n d er$ 600 today. This cost reduction has made comprehensive miRNA profiling accessible to routine research and clinical applications .

Growing Liquid Biopsy Adoption: Liquid biopsy market is projected to reach $8 billion by 2028. MiRNA biomarkers in blood, urine, and other body fluids enable non-invasive cancer detection, treatment monitoring, and recurrence surveillance without surgical biopsies .

Rising Focus on Personalized Medicine: Healthcare systems are shifting from one-size-fits-all treatments to precision medicine approaches. MiRNA expression profiles predict drug response, disease progression, and patient outcomes, enabling tailored therapeutic strategies .

KEY INSIGHT

|> Next-Generation Sequencing (NGS) is the leading technology segment, offering high-throughput comprehensive profiling. Real-time PCR (qPCR) is the fastest-growing segment due to its cost-effectiveness and suitability for targeted validation studies. The consumables segment holds the largest market share, driven by recurring purchases of kits and reagents for miRNA isolation, library preparation, and detection .

Get the full data — free sample available:

→ Download Free Sample PDF: MiRNA Sequencing Assay Market

Includes market sizing, segmentation methodology, and regional forecast tables.

Regional Market Breakdown

*Sources: Market Research Future *

Competitive Landscape

*Sources: Market Research Future *

Outlook Through 2035

The convergence of NGS cost reduction, liquid biopsy acceptance, and AI-powered data analysis will define the miRNA sequencing assay market through 2035. Key trends shaping the market include:

Integration with Multi-Omics Approaches: miRNA sequencing increasingly integrated with genomics, proteomics, and metabolomics for comprehensive disease profiling, enabling systems biology understanding of complex diseases.

AI-Powered Data Analysis: Machine learning algorithms identifying novel miRNA biomarkers from large datasets, reducing analysis time and improving prediction accuracy for disease diagnosis and prognosis.

Point-of-Care Applications: Development of rapid, low-cost miRNA detection platforms for decentralized testing, enabling early cancer screening in community healthcare settings.

Extracellular Vesicle (EV) miRNA Analysis: Growing focus on exosome-derived miRNAs as stable, non-invasive biomarkers for liquid biopsy applications, particularly in oncology and neurology.

Regulatory Approvals for Clinical Use: Increasing number of miRNA-based diagnostic assays receiving FDA and CE-IVD clearance, validating clinical utility and expanding market access.

Emerging Applications in Drug Development: Pharmaceutical companies incorporating miRNA biomarkers into clinical trials for patient stratification, target engagement monitoring, and pharmacodynamic response assessment.

Vendors investing in NGS innovation, AI-powered analytics, point-of-care platforms, and regulatory-approved clinical assays will capture the highest-margin contracts as miRNA sequencing evolves from research tool to essential component of precision medicine diagnostics.

Access complete forecasts, segment analysis & competitive intelligence:

→ Purchase the Full MiRNA Sequencing Assay Market Report (2025-2035)

*10-year forecasts | Segment & application analysis | Regional data | Competitive landscape*

All market projections are forward-looking estimates sourced from WGR’s proprietary research reports and subject to revision.

Source link